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ABSTRACT 
 
BACKGROUND 
The number of patients with colorectal cancers (CRCs) invading the submucosa (pT1) resected 
during colonoscopy is increasing due to the screening. Such tumors are potentially metastatic, but 
only 15% of patients have nodal involvement. Histologic criteria currently used for selecting 
patients needing resection are imprecise and most patients are overtreated. Tumor infiltrating 
lymphocytes (TILs) and mismatch repair (MMR) status impact on CRC prognosis and could be 
risk factors of nodal metastasis. 
 
AIM 
To identify patients requiring completion surgery, the value of histologic variables, TILs, and 
MMR status as risk factors of nodal metastasis was investigated in screening detected and 
endoscopically removed pT1 CRCs. 
 
MATERIALS AND METHODS 
Histologic variables, CD3+ and CD8+ TILs, and MMR status were assessed in 102 endoscopically 
removed pT1 CRC. Univariate and multivariate analyses were used to evaluate the correlation with 
nodal metastasis. 
 
RESULTS 
Positive resection margin, evidence of vascular invasion and tumor budding, wide area of 
submucosal invasion, and high number of CD3+ TILs were associated with nodal metastasis in 
univariate analyses. Vascular invasion was statistically independent in multivariate analysis. 
Evidence of neoplastic cells in the vessels and/or at the excision border featured 5 out of 5 
metastatic tumors and 13 out of 97 non-metastatic ones. 
 
CONCUSIONS 
Completion surgery should be mandatory only for patients with pT1 CRC with vascular invasion 
or with tumor cells reaching the margin. In all other cases, the treatment choice should be entrusted 
to the evaluation of the risk-benefit ratio of each patient considering the rarity of nodal metastasis. 
 
BACKGROUND 
 
Colorectal cancer (CRC) is among the most common cancer for incidence and mortality in high 
income countries, where, however, screening programs are proving effective in reducing mortality 
rates.(1) Indeed, CRC cases and deaths can be prevented through endoscopic removal of 
precancerous lesions and early cancers in asymptomatic patients with positive fecal occult blood 
test (FOBT).(2) Consequently, the number of CRC infiltrating the submucosa (TNM staged as 
pT1) detected and removed during colonoscopy is increasing.(3) The management of such tumors 
is somehow still undefined because they are potentially metastatic, thus completion surgery would 
be necessary to assess nodal status, but the frequency of nodal metastasis is low (about 15% of 
cases).(4) Moreover, up to 20% of patients may experience post-operative complications, thus the 
risk-benefit ratio may be unfavorable.(5) To reduce the number of unneeded bowel resections, 
operation is indicated only in patients with high risk of nodal metastasis according to the features 
of their tumors.(6) However, the histologic variables used vary among countries and in Europe 
seem to be little stringent.(6, 7) The establishment of reliable criteria for the identification of 
patients needing surgery is crucial.  
 In addition to resection margin, vascular invasion, and tumor differentiation, several other 
histologic features have been proposed so far.(6, 8) The most promising seems to be tumor 
budding (a morphologic surrogate of epithelial-mesenchymal transition, a mechanism through 
which neoplastic cells acquire motility and invasiveness) and those measuring tumor microscopic 
extension (i.e. depth, width, and area of the submucosal invasion).(4, 8-13) 
 Number and type of tumor infiltrating lymphocytes (TILs) in CRC have been reported to 
influence tumor behavior and patients’ prognosis.(14) Higher levels of CD3+ and CD8+ TILs 
have been found in CRCs without vascular invasion compared to cases with vessel infiltration.(15) 
Moreover, quantification of CD3+ and CD8+ lymphocytes has been demonstrated to be a valid 
predictor of tumor recurrence and survival.(16-18) 
 CRC with mismatch repair (MMR) deficiency have been associated with a better prognosis 
and with a longer disease free and overall survival compared to MMR-proficient CRC.(19-21) 
Moreover, a lower risk of nodal and distant metastasis at diagnosis have been reported in CRC 
with impaired MMR system, independently of the pathologic features of the tumor.(22) It has also 
been observed that poor differentiation worsens the prognosis of CRC patients only if associated 
with MMR proficiency, suggesting that the MMR status of the tumor should be included in the 
grading of CRC to better stratify patients.(23)  
 Since both a low amount of CD3+ and CD8+ TILs and MMR proficiency have been 
associated with a worse CRC prognosis in terms of survival, the hypothesis is that these variables 
could be correlated also to nodal metastasis. 
AIM 
 
The aim of this study was to investigate the value of histologic variables, CD3+ and CD8+ TILs, 
and MMR status as risk factors of nodal metastasis to aid in the clinical decision-making process 
whether to operate or not patients with screening detected and endoscopically removed pT1 CRC.  
MATERIALS AND METHODS 
Patients 
This retrospective study was conducted on 102 consecutive asymptomatic and FOBT positive 
patients with a pT1 CRC endoscopically resected as a whole (i.e. fragmented cases were excluded) 
during the period 2009-2015 among the CRC screening program of Padua. According with 
European guidelines, patients had been divided into low risk of nodal metastasis (48 patients) and 
high risk of nodal metastasis (64 patients).(6) Completion surgery was performed in 63 patients 
(52 patients of the high risk group and 11 patients of the low risk group who opted for the 
operation). Seven high risk patients refused the bowel resection and five were not eligible for 
surgery due to comorbidities. Follow-up schedules for all the patients are summarized in Table 
1.(24-26) None of the patients had distant metastasis at the time of the initial diagnosis. All 
procedures were performed accordingly with the 1964 Helsinki declaration and its later 
amendments. This study adheres to REMARK guidelines.(27)  
Table 1. Follow-up schedules of the groups of patients. 
Variable Non-operated patients 
Operated patients 
(non-metastatic) 
Operated patients 
(metastatic) 
Clinical visit 
After 3 mos and 
then every yr for 5 
yrs 
Every 6 mos for 5 
yrs 
Every 3 mos for 2 yrs 
and then every 6 mos for 
3 yrs 
Colonoscopy 
After 3 mos and 
then every yr for 5 
yrs 
After 1, 2, and 5 yrs After 1, 2, 5, and 10 yrs 
Serum CEA and CA 
19-9 
After 3 mos and 
then every yr for 5 
yrs 
Every 6 mos for 5 
yrs 
Every 3 mos for 2 yrs 
and then every 6 mos for 
3 yrs 
Thoracoabdominal 
contrast-enhanced 
CT 
After 3 mos and 
then every yr for 5 
yrs 
Every yr for 5 yrs 
Every 6 mos for 3 yrs 
and then every yr for 2 
yrs 
Abdominal US After 2 and 4 yrs - - 
CEA = carcinoembryonic antigen; CT = computed tomography; US = 
ultrasonography. 
 
Histology 
Information regarding tumor location (divided into right, transverse, and left colon, and sigmoid 
colon-rectum), type (pedunculated and non-pedunculated tumor), and size (expressed in cm) were 
recovered from the histological reports. The H&E-stained original slides of each case were 
reviewed to evaluate the variables described below. Resection was regarded as incomplete when 
invasive tumor cells were observed at or within 1 mm of the excision margin (identified by ink or 
diathermy effect).(6) This data was further refined by recording also if the cells reached the 
resection border. Cases in which incorrect sample orientation did not allow a sure recognition of 
the margin were recorded as not evaluable. Unlike WHO classification, histologic grade was 
determined by the less differentiated area of the invasive cancer regardless of its amount and it was 
divided into low and high grades.(28, 29) Vascular invasion was defined as presence of tumor cells 
within endothelial-lined channels. Tumor budding, a single tumor cell or a cell cluster consisting 
of four tumor cells or less at the invasive front of the cancer, was assessed according to Lugli and 
colleagues using Leica DM4000 B microscope (Leica Biosystems, Newcastle upon Tyne, UK) with 
an objective magnification of 20x and an eyepiece FN diameter of 22 (normalization factor used 
= 1.210) and recorded both as present/absent, number of buds, and budding category (Bd 1 = 0-
4 buds; Bd 2 = 5-9 buds; Bd 3= 10 or more buds).(30) The depth of submucosal invasion was 
evaluated according to the criteria reported by Kawachi and colleagues and expressed in mm.(9) 
In pedunculated lesions with infiltration of the submucosa confined to the head of the polyp, the 
depth was considered 0 mm. The width and the area of submucosal invasion were assessed 
following the definition of “maximum width of carcinoma” and “total area of submucosal invasion 
by carcinoma” used by Toh and colleagues and were expressed in mm and mm2, respectively.(10) 
These last three variables were evaluated on virtual slides using the Aperio ImageScope viewing 
software (Leica Biosystems) on virtual slides obtained by scanning the H&E-stained original slides 
with a Leica SCN400 Slide Scanner (Leica Biosystems). 
Immunohistochemistry 
Immunohistochemistry was performed as described elsewhere on 4 μm thick consecutive sections 
from the most representative FFPE sample of each case with the primary antibodies listed in Table 
2.(31) MLH1, MSH2, MSH6, and PMS2 immunoreactions were interpreted following the criteria 
stated by Shia and colleagues to assess MMR system status.(32, 33) 
Table 2. Antibodies used in the study. 
Antibody Clone Company Dilution 
CD3 LN10 Leica Biosystems, Newcastle upon Tyne, UK 1:100 
CD8 C8/144B Agilent Technologies, Santa Clara, USA 1:50 
MLH1 ES05 Agilent Technologies, Santa Clara, USA 
1:25 
MSH2 FE11 
Agilent Technologies, Santa Clara, USA 1:25 
MSH6 EP49 
Agilent Technologies, Santa Clara, USA 1:25 
PMS2 EP51 Agilent Technologies, Santa Clara, USA 1:25 
 
Image analysis 
All the CD3 and CD8 immunostained slides were scanned with a Leica SCN400 Slide Scanner 
(Leica Biosystems). Virtual slides were imported in the Visiopharm image analysis environment 
(version 4.5.6.5; Visiopharm, Horsholm, Denmark). The consecutive CD3 and CD8 virtual slides 
of each case were aligned using the Tissuealign add-on (Visiopharm), thus providing precise 
stacking of the tissue sections. The region of interest (ROI), i.e. the area of submucosal invasion 
of the tumor, was outlined on each CD3 immunostained virtual slide and automatically reproduced 
by the program on the aligned CD8 immunostained virtual slide. Automated quantification of 
CD3+ and CD8+ lymphocytes within the ROI, expressed as number and density (number of 
immunostained cells per mm2), was achieved using a custom-made algorithm created with the 
Visiopharm software.  
Statistical analysis 
Fisher’s exact test was used to investigate associations between categorical variables and groups of 
patients. Normality of the distribution of the continuous variables was assessed by both graphical 
(boxplot and qq-plot) and formal methods (Shapiro-Wilk test). Without normality, Wilcoxon rank-
sum test with continuity correction was used to assess significant differences between groups of 
patients. Receiver-operating characteristic (ROC) curve and the area under the ROC curve (AUC) 
were used to assess the ability of selected variables to differentiate between groups of patients. 
Youden procedure was applied to determine the best threshold value. All the variables that were 
significantly correlated with nodal metastasis in the univariate analyses were considered as 
covariates in a multivariate penalized logistic regression model. Model performance was assessed 
with ROC curve and AUC. Sensitivity, specificity, positive predictive value (PPV), and negative 
predictive value (NPV) of the best combination of risk factors were calculated. A p<0.05 was 
considered statistically significant. All statistical analyses were performed using the R software (R 
Foundation for Statistical Computing, Vienna, Austria). 
RESULTS 
 
Clinical findings 
Patients were 61 males and 41 females, with mean age of 62.2±6.1 years. The mean length of the 
63 resected bowel tracts was 18.1±10.6 cm and the mean number of harvested lymph nodes was 
7.5±5.6. In 9 cases (resection length range: 5.5-13.0 cm) less than 12 lymph nodes were found, 
although the perivisceral fat was completely included; in 4 of these cases, no lymph nodes were 
detected. Residual disease was found in 3 resections, nodal metastasis in 4 cases, and in one case 
both residual tumor and nodal metastasis were present.  
The mean follow-up duration was 48.7±23.0 months in the non-operated group and 
50.1±22.5 months in the operated one. Two patients left the follow-up after 2 and 4 months of 
surgery (no residual tumor and nodal metastasis were present in their resections). One patient of 
the non-operated group had a local tumor relapse detected by colonoscopy after 4 years. No 
patients had nodal or distant metastasis or died during the follow-up period.  
 
Univariate analyses of nodal metastasis 
Results of the univariate analyses of nodal metastasis (present in 5 out of 102 patients) are 
summarized in Table 3. Incomplete endoscopic resection was correlated with nodal metastasis 
(p<0.05). Tumor cells reached the excision margin in 3 out of 5 metastatic tumors, were observed 
at a distance less than 1 mm in one of these cases, and in the last one the resection was complete. 
The rate of tumors with vascular invasion (Figure 1) was greater in the group with nodal 
involvement than in that without it (80.0% and 7.2%, respectively; p<0.05). Tumor budding 
(Figure 1), regardless of the recording mode (i.e. presence of buds, number of buds, or tumor 
budding category), was associated with nodal metastasis (all p<0.05). As for tumor budding 
category, Bd1 was compared with Bd2 and Bd3 grouped together due to the paucity of cases in 
these last classes. Depth of submucosal invasion was higher in tumors with nodal metastasis than 
in those without it, however the difference was not statistically significant. The minimum depth of 
submucosal invasion in metastatic tumors was 3.4 mm; 45 non-metastatic tumors had higher 
values. Eighty-nine tumors without nodal involvement were deeper than the threshold of 1 mm.(7) 
ROC curve was plotted using the depth of submucosal invasion measurements and the calculated 
AUC was 0.74. The best threshold value obtained was 4.9 mm; 3 tumors with nodal metastasis 
and 26 tumors without nodal metastasis were deeper than this value. An increased area of 
submucosal invasion was correlated with nodal metastasis (p<0.05). The minimum area of 
submucosal invasion in metastatic tumors was 55.2 mm2; 15 non-metastatic tumors had higher 
values.  
The number of CD3+ TILs (Figure 2) was higher in tumors with nodal involvement than 
in those without it (p<0.05). The AUC of CD3+ TILs was 0.87 and the best threshold was 95,045 
lymphocytes; all the metastatic and 26 non-metastatic tumors had higher values. Despite density 
of CD3+ TILs was higher in the metastatic tumors than in the non-metastatic ones, the difference 
was not statistically significant. Sex, age, tumor location, type, and size, histologic grade, width of 
submucosal invasion, MMR status, and number and density of CD8+ TILs (Figure 2) were not 
associated with nodal metastasis. All the tumors with nodal metastasis were low grade and MMR-
proficient, thus it was not possible to investigate the prognostic value of the histologic grade 
integrated with the MMR status. 
 
 Figure 1. Photomicrograph of one of the endoscopically removed colorectal cancer infiltrating 
the submucosa included in this study showing tumor buds (black arrows) and vascular invasion (red 
arrow). Original magnification 400x. 
 
 Figure 2. The images show the region of interests (green line) outlined in the CD3 (A) and CD8 
(B) immunostained virtual slides and the automated quantification of the lymphocytes (in red in the 
insets) of one of the endoscopically removed colorectal cancer infiltrating the submucosa included 
in this study. Original magnification 20x and 400x. 
 
  
Table 3. Univariate analysis of all the variables for nodal metastasis. 
Variable Negative for nodal metastasis (%) 
Positive for nodal 
metastasis (%) p-value 
Number of patients 97 (95.1) 5 (4.9)  
Sex 
     Male 
     Female 
 
59 (96.7) 
38 (92.7) 
 
2 (3.3) 
3 (7.3) 
 
 
NS 
Age (years) 
     Mean±s.d. 
 
62.2±6.1 
 
60.8±6.8 
 
NS 
Tumor location 
RC/TC/LC/SR 
 
6/3/5/83 
 
0/0/0/5 
 
NS 
Tumor type 
     Pedunculated 
     Non-pedunculated 
 
40 (95.2) 
58 (95.0) 
 
2 (4.8) 
3 (5.0) 
 
 
NS 
Tumor size (cm) 
     Mean±s.d. 
 
1.8±1.0 
 
1.6±0.3 
 
NS 
Resection margin 
     Not evaluable 
     >1 mm 
     ≤1 mm 
 
3 (100) 
55 (98.2) 
39 (90.7) 
 
0 (0.0) 
1 (1.8) 
4 (9.3) 
 
 
 
<0.05 
Histologic grade 
     Low grade 
     High grade 
 
84 (94.7) 
13 (100) 
 
5 (5.3) 
0 (0.0) 
 
 
NS 
Vascular invasion 
     Absent 
     Present 
 
90 (99.0) 
7 (63.6) 
 
1 (1.0) 
4 (36.6) 
 
 
<0.05 
Tumor budding 
     Absent 
     Present 
 
81 (97.6) 
16 (84.2) 
 
2 (2.4) 
3 (15.8) 
 
 
<0.05 
Number of buds 
     Mean±s.d. 
 
1.0±3.0 
 
2.6±2.5 
 
<0.05 
Tumor budding category 
     Bd1 
     Bd2 
     Bd3 
 
92 (96.7) 
2 (50.0) 
3 (100.0) 
 
3 (3.3) 
2 (50.0) 
0 (0.0) 
 
 
 
<0.05a 
Depth of submucosal invasion (mm) 
     Mean±s.d. 
 
4.0±2.4 
 
5.3±1.9 
 
NS 
Width of submucosal invasion (mm) 
     Mean±s.d. 
 
6.3±3.6 
 
7.1±2.3 
 
NS 
Area of submucosal invasion (mm2) 
     Mean±s.d. 
 
39.5±36.6 
 
73.0±32.7 
 
<0.05 
Mismatch repair (MMR) status 
     MMR-proficiency 
     MMR-deficiency 
 
89 (94.7) 
8 (100.0) 
 
5 (5.3) 
0 (0.0) 
 
 
NS 
CD3+ TILs number 
     Mean±s.d. 
 
83,417.9±128,468.7 
 
168,657.5±61,750.1 
 
<0.05 
CD3+ TILs density (number/mm2) 
     Mean±s.d. 
 
1,942.9±1,585.3 
 
2,839.9±2,128.2 
 
NS 
CD8+ TILs number 
     Mean±s.d. 
 
14,755.1±27,201.3 
 
27,855.3±22,504.2 
 
NS 
CD8+ TILs density (number/mm2) 
     Mean±s.d. 
 
331.2±260.5 
 
375.8±245.3 
 
NS 
RC = Right colon; TC = Transverse colon; LC =Left colon; SR = Sigmoid colon-rectum; NS = 
Not significant; TIL = Tumor infiltrating lymphocyte. 
a Bd1 compared with Bd2 and Bd3 grouped together. 
 
Multivariate analysis of nodal metastasis 
Multivariate analysis by a penalized logistic regression model using resection margin, vascular 
invasion, tumor budding category, area of submucosal invasion, and number of CD3+ TILs 
showed that nodal metastasis was independently correlated only with presence of vascular invasion 
(Table 4). Vascular invasion was evident in 4 out of 5 metastatic CRCs and in 7 out of 97 non-
metastatic ones. Adding the status of resection margin, defined as evidence of tumor cells at the 
resection border, guarantees the identification of all the metastatic cases (5 out of 5) minimizing 
the number of those without metastasis (13 out of 102). This combination of risk factors showed 
a sensitivity of 100%, a specificity of 87%, a PPV of 28%, and a NPV of 100%. 
  
Table 4. Multivariate analysis of the five significative variables for nodal metastasis 
using a penalized logistic regression model. 
Variable Estimate 95% Confidence Interval p-value 
Vascular invasion 3.07 -0.37-11.03 <0.05 
Resection margin -1.63 -6.41-0.66 NS 
Tumor budding category 2.23 -1.77-11.66 NS 
Area of submucosal invasion 0.02 -0.19-0.12 NS 
CD3+ TILs number 0.01 0.01-0.02 NS 
NS = Not significant  
 
Correlations between variables 
Presence of buds, high number of buds, and high tumor budding categories were strongly 
associated with vascular invasion (all p<0.05). Number and density of CD3+ TILs were correlated 
neither with vascular invasion nor with MMR status. Contrary to vascular invasion, MMR-
deficiency was significantly correlated both with high number and density of CD8+ TILs (p<0.05). 
Histologic grade was not associated with MMR status. 
DISCUSSION AND CONCUSIONS 
 
Nodal metastasis in pT1 CRC is infrequent, accounting for about 15% of cases.(4) In this series 
its prevalence was 4.9%, in line with previous findings indicating that in non-Asian populations it 
can be slightly lower.(4) Using the current European criteria for the risk assessment of nodal 
metastasis, more than half of the patients underwent completion surgery.(6) However, only 5 out 
of the 63 operated patients had nodal metastasis, thus in 92.0% of cases there was an overtreatment 
strongly highlighting the need to adopt more reliable criteria. Moreover, in 9 resections less than 
12 lymph nodes (the minimum number for applying TNM staging) were harvested, thus the 
intervention was useless from this point of view.(34) These resections were much shorter than the 
others. Anyway, neither nodal nor distant metastases were found during the follow-up.  
As for residual disease, in all the 3 cases without nodal involvement the CRCs had been 
endoscopically removed from the sigmoid colon-rectal region; these tumors were low grade and 
lacked vascular invasion, however their distance from the excision border was equal to or less than 
1 mm. Probably in these cases a mucosectomy would be more appropriate than a surgical resection. 
In the remaining case, the sigmoid-rectal tumor was well differentiated, with a free resection 
margin, but with neoplastic cells in the vessels, thus the probability of nodal metastasis was high 
and surgery the right option. The only event found in this CRC screening population during the 
follow-up was a local tumor recurrence after 4 years. The previous pT1 tumor was low grade, 
without vascular invasion, but with a resection margin not evaluable. The patient refused both the 
intervention and the mucosectomy (the more prudent choices) by opting for the follow-up. 
Concerning histologic variables, our results confirmed the association between nodal 
metastasis and positive resection margin, evidence of vascular invasion, presence of tumor 
budding, and wide area of submucosal invasion.(4, 8-12, 35-37) This makes sense because tumor 
cells reach the lymph nodes through lymphatic vessels, thus vascular invasion is a prerequisite for 
nodal metastasis and its detection is a cornerstone in defining the metastatic risk of a tumor. 
However, cases occur in which vascular invasion is not observed in histology, despite the presence 
of metastasis in the draining lymph nodes. Indeed, histology evaluates one or more internal plane 
of a three-dimensional lesion, but it may happen that the visualized sections did not sampled (and 
therefore documented) the zone with vascular invasion. Similarly, when a pT1 CRC is incompletely 
removed during colonoscopy, a part of the lesion cannot be analyzed histologically. This part of 
the tumor could have already infiltrated the vessels or, if left in place, could metastasize in the 
future. In the metastatic process, tumor budding is the upstream phase of vascular invasion and, 
in this series, there was a strong correlation between tumor budding and vascular invasion. 
Through the mechanism of epithelial-mesenchymal transition, cancer cells are thought to acquire 
motility and invasiveness, to detach from the tumor mass, to infiltrate the extracellular matrix as 
single cells or small clusters (the tumor buds), and to penetrate in the lymphatic vessels.(4, 12) 
According to the literature, our findings showed that a single tumor bud already confers an 
increased risk of nodal metastasis and that this is greater the more the tumor buds are numerous.(4, 
8, 9, 11, 12) Tumor budding categorization is a practical and standardized method to quantify this 
variable and is reliable in identifying cases with a higher risk of nodal involvement.(4, 30) In this 
series of pT1 CRCs, there was a significant correlation between the area of submucosal invasion 
and nodal metastasis. Tumors with larger area of infiltration are more likely to encounter the 
lymphatic vessels of the upper third of the submucosa (where the density of the vessels is higher) 
and thus have more chances to invade them.(10, 38) Our results showed that 15 CRCs without 
nodal involvement had an area larger than the smallest one among the metastatic cases. Moreover, 
the median area of submucosal invasion of tumors with nodal metastasis reported by Toh and 
colleagues was smaller than the median in this series (54.1 mm2 and 65.0 mm2, respectively).(10) 
Despite the available data are too few to draw conclusions, it seems likely that the number of false 
positive and false negative cases setting a threshold for this variable will be too high to be useful 
in clinical practice . Moreover, a precise measurement of the area is time consuming, since it 
requires image analysis of virtual slides. Another limit is that depth, width, and area of submucosal 
invasion are all affected by the sampling of the gross specimen. Indeed, the point and the angle of 
the cut can have an enormous impact on these measurements.(39) Contrary to literature, in this 
study neither depth nor width of submucosal invasion were correlated to nodal metastasis, despite 
the measurements were higher in the metastatic group.(8-10) A possible explanation could be the 
higher rate of pedunculated tumor in our series; long stalks can host deep and narrow tumor 
infiltrations. Anyway, about 90% and 50% of our CRCs, respectively, exceeded the commonly 
used depth (1 mm) and width (5 mm) thresholds for assessing the tumor metastatic risk. Moreover, 
these methods are quite subjective (e.g. positioning the “Haggitt” lane) and difficult to apply (e.g. 
mucosal ulceration).(8, 9) Contrary to literature, histologic grade was not associated with nodal 
metastasis, despite the less stringent criteria for assigning a high grade.(8, 28, 29) The fact that all 
the metastatic CRCs were low grade demonstrates that differentiation of the tumor not necessarily 
corresponds to its disseminating ability. Anyway, this result impaired part of this study because it 
was not possible to test the prognostic value of the combination between high histologic grade 
and MMR proficiency. Despite all the 8 MMR-deficient CRCs were in the non-metastatic group 
of patients, MMR status was not correlated with nodal involvement, contrary to the findings of 
Malesci and colleagues.(22) CRCs with MMR deficiency carried higher number and density of 
CD8+ TILs compared to MMR-proficient cases, as found by other authors.(40, 41) In MMR-
deficient tumors, known to have a high mutagenic potential, the accumulation of mutations leads 
to the production of neo-antigens, enhancing the anti-tumor immune response.(41-43) 
Surprisingly, a higher number of CD3+ TILs was found in CRCs with nodal metastasis compared 
to those without it. This is the opposite of what has been reported in literature so far, where it has 
been shown that an intense immune response was usually associated with a better prognosis in 
terms of survival.(14-18) Moreover, Pages and colleagues have found that increased levels of 
CD3+ TILs were correlated with absence of vascular invasion, a data not confirmed in this 
series.(15) Anyway, the quantification of CD3+ TILs seems inappropriate to select patients for 
completion surgery since about 30% of cases (including all the metastatic ones) had values higher 
than the best threshold. The number of CD3+ TILs is increased in such tumors, but they may be 
ineffective. Indeed, metastatic tumors could have implemented immune escape mechanisms 
producing immunosuppressive molecules.(44) Otherwise, these lymphocytes could be mostly T 
helper 17 (Th17) cells, a subset of pro-inflammatory T-lymphocytes characterized by the 
production of interleukin 17 that has been correlated with nodal metastasis and poor prognosis in 
CRC.(45, 46) 
Evidence of vascular invasion was the only statistically independent factor by multivariate 
analysis, but it failed in identifying a metastatic tumor. Thus, the addition of another variable was 
required. A selection system based on the detection of tumor cells in the vessels or at the excision 
margin would have prevented 45 unnecessary resections without losing any metastatic tumor. 
Thus, completion surgery should be mandatory only in cases with these features. In all other cases, 
given the rarity of nodal metastasis, mucosectomy and follow-up or follow-up alone can be valid 
alternative to completion surgery, and a treatment decision should be taken by the multi-
disciplinary team after an appraisal of the risk-benefit ratio of each patient. 
A strength of this study lies in the homogeneous features of the investigated population: i) 
patients were consecutive, demographically similar, and all asymptomatic with positive FOBT at 
the time of inclusion; ii) initial treatment was the same for all; iii) scheduled follow-up was strictly 
observed; iv) abandonment rate was 1.9% and only after surgery. Variables were analyzed only in 
non-surgical specimens (analogy of material), adhering to their definitions and evaluating methods 
(comparability of results), and, when possible, using image analysis technology (objectivity of 
result). The main weaknesses concern the retrospective setting and the limited number of collected 
cases that did not allow to perform some evaluations. Indeed, additional larger studies are required 
to confirm these findings, to better characterize TILs in relation to nodal involvement and to 
explore if MMR-proficient high grade CRCs have an increased risk of nodal metastasis. 
In conclusion, positive resection margin, presence of vascular invasion, high tumor 
budding categories, large area of submucosal invasion, and high number of CD3+ TILs are risk 
factors of nodal metastasis in screening detected and endoscopically removed pT1 CRCs. In the 
clinical decision-making if completion surgery is required or not, it seems that resection is 
mandatory only for tumor in which neoplastic cells reach the excision border or are found inside 
the vessels. In all other cases, multi-disciplinary team should choose the treatment after the 
evaluation of the risk-benefit ratio of each patient considering that nodal metastasis is rare. 
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